Business Summary
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Research and Development
100.0
%
| 9 | 100.0 % | 5 | 100.0 % | -38.93% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Gavin M. Spencer
CEO | Chief Executive Officer | 53 | 01/05/01 |
Michele Garufi
FOU | Founder | 70 | 15/96/15 |
Sandrine Gestin
DFI | Director of Finance/CFO | 56 | 01/99/01 |
Doug Hubatsch
CTO | Chief Tech/Sci/R&D Officer | - | 13/21/13 |
General Counsel | - | 01/02/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Les Kaplan
BRD | Director/Board Member | 73 | 01/14/01 |
Director/Board Member | 65 | 18/17/18 | |
Adrienne Graves
BRD | Director/Board Member | 69 | 08/14/08 |
Michele Garufi
FOU | Founder | 70 | 15/96/15 |
Chairman | 73 | 16/10/16 | |
Director/Board Member | 71 | 11/14/11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,170,498 | 46,850,128 ( 93.38 %) | 288,965 ( 0.5760 %) | 93.38 % |
Company contact information
Nicox SA
Drakkar 2 - Bât D 2405 route des Dolines
06560, Sophia-Antipolis
+33 4 97 24 53 00
http://www.nicox.comSector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |